TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling

OBJECTIVE: More than half of human glioblastomas show EGFR gene amplification and mutation, but EGFR inhibitors have not been effective in treating EGFR-positive glioblastoma patients. The mechanism behind this type of primary resistance is not well understood. The aim of this study was to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Li, She, Chunhua, Shi, Qian, Yin, Qiang, Ji, Xinxin, Wang, Yongrong, Fan, Yulong, Kong, Xinyao, Li, Peng, Sun, Zengfeng, Zhang, Xiaohui, Zhang, Zhen, Wang, Jian, Wang, Tong, Xu, Yuanfu, Li, Wenliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743627/
https://www.ncbi.nlm.nih.gov/pubmed/31565489
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743627/
https://www.ncbi.nlm.nih.gov/pubmed/31565489
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0011

Ejemplares similares